Amryt Pharma, the pharma company focusing on developing treatments for patients with rare and orphan diseases, has today announced a trading update for the nine months to 30th September 2019, the first since acquiring Aegerion Pharmaceuticals Inc in September. Following completion of the acquisition, Amryt now has two commercial-stage assets, Juxtapid® / Lojuxta® (lomitapide) and Myalept® / Myalepta® (metreleptin) and infrastructure in place through which the Company is commercialising these assets in North America, EMEA and LATAM. On a pro forma basis:

• • Revenues of $113.1M, compared with $94.5M for the same period in 2018 representing a growth rate of 19.7%
  • Juxtapid®/ Lojuxta® (lomitapide) generated revenues of $51.1M compared with $48.0M for the same period in 2018 representing a growth rate of 6.5%
  • Myalept® / Myalepta® (metreleptin) generated revenues of $61.7M, compared with $45.8M for the same period in 2018 representing an increase of 34.7%
  • The significant growth in metreleptin was driven by the rollout of Myalepta® in Europe following the approval of the product by the EMA (European Medicines Agency) in Q3, 2018
• At 31 October 2019 the Group had cash on hand of US$61.2m (unaudited)

ANNOUNCEMENT IN FULL